Ambrx signs bispecific antibody tech deal with Zhejiang Hisun
Ambrx says it will use its antibody platform in its collaboration with Zhejiang Hisun Pharmaceutical Company to develop and commercialise bispecifics for the treatment of cancer.
Archives for May 26, 2014
UCL spin-out aims to smuggle antibodies across the blood-brain barrier
A collaboration involving academia and industry is to develop new ways of delivering antibodies to the brain using molecular envelop technology developed by Nanomerics, a UCL spin-out company.